Carisbamate is an investigative neuromodulator that was developed for the treatment of epilepsy. The mechanism of action of carisbamate is not fully understood. However, there is evidence suggesting that one mechanism carisbamate exerts its antiepileptic effects through inhibition of voltage-gated sodium channels. Antiepileptic drugs may exert their effects by interfering with the neuronal GABA systems (3). Another study provided evidence suggesting that the mechanism of action is carisbamate’s ability to block T-type calcium channels in neurons and prevent excessive intracellular calcium accumulation. Carisbamate also inhibits voltage-gated sodium channels and can modulate the activation of a GABA mediated chloride conductance.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Carisbamate, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.